首页> 外文期刊>肺癌 >Clinical and pathological evaluation of primary mucoepidermoid carcinoma of the lung
【24h】

Clinical and pathological evaluation of primary mucoepidermoid carcinoma of the lung

机译:肺部原发性粘膜蛋白癌的临床和病理学评价

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Objective and Methods. We performed clinical and immmohistochemical examination of 8 patients with primary mucoepidermoid carcinoma of the lung who were operated on in our hospital; these patients represented 0.55% of all cases of primary lung cancer. Results. The mean patient age at the time of the operation was 41.9 ?14.9 years, and the male-to-female ratio was 5:3. Chief complaints were bloody sputum in 2 patients, chest pain in 1, and fever in 1. However, the remaining 4 patients had no symptoms. The tumor was in the trachea and peripheral bronchus in 1 patient each. In the remaining 6 patients, the tumor was between the main bronchus and the segmental bronchus. Chest X-ray revealed a mass shadow in 5 patients and atelectasis in 1 patient. However, X-ray revealed no findings in the remaining 2 patients. Segmental tracheal resection, lobectomy, and pneumonectomy were performed in 1, 5, and 2 patients, respectively. Complete resections were performed in all patients. Seven patients were able to be examined immunohistochemically. These patients had a diploid pattern on DNA histograms. However, only 1 of these patients with lymph node metastases had positive staining for p53 and MIB-1; this patient died due to recurrence 3 years and 5 months after the operation. Conclusion. MIB-1 and p53 immunostaining may be useful when judging malignant potential in patients with pulmonary mucoepidermoid carcinoma.
机译:目标与方法。我们对8例肺部含有肺泡癌患者进行了临床和免疫组化检查,在我们院内运营的肺部;这些患者占所有原发性肺癌病例的0.55%。结果。操作时的平均患者年龄为41.9?14.9岁,雄性与女性比例为5:3。在2名患者中,首席投诉是血液痰,胸部疼痛1,发烧1.然而,剩下的4例患者没有症状。肿瘤在1例患者中在气管和外周支气管中。在剩下的6例患者中,肿瘤在主支气管和节段支气管之间。胸部X射线显示5名患者的肿块阴影和1例患者。然而,X射线在剩余的2名患者中没有显示出现。在1,5和2名患者中进行节段性气管切除,肺切除术和肺切除术。在所有患者中进行完全切除切除。 7名患者能够免疫组织化学检查。这些患者在DNA直方图上有二倍体模式。然而,这些淋巴结转移的这些患者中只有1例P53和MIB-1具有阳性染色;该患者因手术后的3岁和5个月而死亡。结论。 MIB-1和P53免疫染色在判断肺粘膜体蛋白癌患者的恶性潜力时可能是有用的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号